期刊
EXPERT REVIEW OF NEUROTHERAPEUTICS
卷 19, 期 11, 页码 1127-1133出版社
TAYLOR & FRANCIS LTD
DOI: 10.1080/14737175.2019.1648210
关键词
Neuromyelitis optica spectrum disorders (NMOSD); diagnostic criteria; immunopathogenesis; aquaporin-4 immunoglobulin G (AQP4-IgG); myelin oligodendrocyte glycoprotein immunoglobulin G (MOG-IgG); standard treatment; emerging treatment; management
资金
- MedImmune/Viela Bio
Introduction: Neuromyelitis optica spectrum disorders (NMOSD) are autoimmune diseases of the central nervous system mainly involving the optic nerves and spinal cord. Many advances have been made in understanding the immunopathology of NMOSD and related clinical classification, nevertheless, open issues in management and effective therapeutic approaches still remain. Areas covered: In this article, the authors reviewed and discussed the scientific evidence in pathogenesis and pharmacological therapy of NMOSD addressing the more recent advances in new biological treatment option and therapeutic strategy that may help to improve management of this condition. Expert opinion: Despite current immunopathogenic evidence, NMOSD management represents a challenge due to the poor-validated diagnostic, prognostic and therapeutic biomarkers. A tailored approach is mandatory to improve the management of the different disease clinical settings.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据